Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%

May 14, 2020
Takeda Pharmaceutical’s group sales in FY2019 rose nearly 57% over the previous year as its revenue was bolstered by its Shire buyout in January last year, but operating profit shriveled by some 58% due to acquisition-related outlays, the company said...read more